Health Canada’s Response to COVID-19

by | Apr 17, 2020 | Coronavirus, COVID-19, FDA, Medical Devices, Pharma, Quality Systems, Requirements

Canada has been facing the same difficulties as many other nations due to the novel coronavirus. In light of the shortage of medical equipment and the PPEs, Health Canada relaxed their policies to let medical equipment and other necessary supplies to be distributed in Canada. Below are some of the policies that Health Canada rolled out to prevent shortages of supplies and ensuring that safe and effective products are distributed in the market for use.1

Health Canada published an interim order that stays in effect during the public health emergency which allows for the import of medical devices that are essential in relation to COVID-19. The order allows for such devices to be imported and exempts manufacturers from complying with the Canadian Medical Device Regulations, application fees and the requirement for the manufacturer to hold an MDSAP certification.1

A guidance document was released by Health Canada that addresses the supply of gloves, gowns, face masks and respirators. According to the guidance document, Health Canada is providing fast track approvals of PPEs that follow the appropriate labeling requirements and risk mitigation measures. Health Canada is also providing fast track approvals to import noncompliant masks such as those gone beyond their shelf life to boost their supply of PPEs.1

Health Canada also released a notice regarding the policy that covers fast track approvals for ventilators. The notice allows for an expedited review of COVID-19 medical devices. Health Canada encouraged manufacturers to use the FDA’s temporary policy for granting Emergency Use Authorizations for ventilators in addition to Health Canada’s required review elements when submitting their fast track approval applications. Some of the required elements are:2

  1. Device description
  2. Design philosophy that compares the similarities and differences between the subject ventilator and any other similar licensed ventilators in Canada or other countries
  3. Labeling documents
  4. Marketing history
  5. Declaration of Conformity (DOC) to Health Canada recognized standards
  6. Summary of bench testing
  7. Summary of software verification and validation
  8. Summary of clinical evidence

Have more questions about Health Canada? Call us today at 248-987-4497 or email us at info@emmainternational.com.


1Emergo (April2020) Health Canada responds to COVID-19 emergency retrieved on 04/15/2020 from https://www.emergobyul.com/blog/2020/04/health-canada-responds-covid-19-emergency

 

2Health Canada (March 2020) Notice: Importation or sale of ventilators – use of US FDA guidance and Canadian requirements for authorization under the Interim Order retrieved on 04/15/2020 from https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/covid19-notice-importation-sale-ventilators.html#a2

 

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This